Diabetes Mellitus Clinical Trial
— PRO-MENTALOfficial title:
PRO-MENTAL: Precision Mental Health in Diabetes - Subtypes of Mental Health, Trajectories, and Patterns With Glycaemic Control
PRO-MENTAL is a non-interventional, prospective, observational study investigating longitudinal associations between diabetes distress, mental disorders, and glycemic outcomes in people with type 1 diabetes (T1D) and type 2 diabetes (T2D). The study aims to determine mental health subtypes, trajectories, and patterns and to advance a precision medicine approach to improve mental health in people with diabetes through personalized care and interventions. A total of 1500 people with T1D or T2D will participate in the study, running over a 24-month period. Participants will be recruited at different levels of diabetes care including specialized centers and hospitals. The assessment includes a baseline assessment (clinical interview, questionnaire survey, and laboratory assessment) and four subsequent measurement time points - every six months - to a total period of two years. Each measurement time point includes an online questionnaire survey as well as a 14-day ambulatory assessment of daily mental and somatic variables (smartphone-based ecological momentary assessment (EMA) of daily sleep quality, mood, stress, and diabetes-related burdens/distress, as well as continuous glucose measurement (CGM) of daily glucose levels). The study uses precision monitoring to identify evidence-based subgroups of people with diabetes with regard to mental disorders/problems and glycemic outcome. Epidemiological data regarding prevalence and incidence rates of depression, anxiety, and eating disorders will be analyzed, and patient trajectories and patterns will be determined. The study also aims to shed more light on the mediating mechanisms between mental health and glycemic outcomes. The findings of the study will be used as the basis to develop a precision medicine approach with personalized interventions for specific sub-groups of people with type 1 and type 2 diabetes.
Status | Recruiting |
Enrollment | 1500 |
Est. completion date | December 31, 2024 |
Est. primary completion date | September 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Age between 18 and 75 years - Diagnosis of type 1 diabetes (T1D) or type 2 diabetes (T2D) - Diabetes duration = 1 year - Sufficient German language skills - Written informed consent Exclusion Criteria: - Inability to consent, - Significant cognitive impairment (e.g., cognitive disorder, dementia) - Severe somatic disease or mental disorder likely to impede study participation or confound results (e.g., severe heart failure = NYHA III; cancer requiring treatment; dialysis-dependent nephropathy; schizophrenia/psychotic disorder) - Terminal illness - Being bedridden |
Country | Name | City | State |
---|---|---|---|
Germany | Diabetes Center Mergentheim | Bad Mergentheim | Baden-Württemberg |
Germany | Diabetes Practice Mergentheim | Bad Mergentheim | Baden-Württemberg |
Lead Sponsor | Collaborator |
---|---|
Forschungsinstitut der Diabetes Akademie Mergentheim |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | COVID-19-related burden | COVID-19-related burden is assessed as control variable at baseline, 12-month FU, and 24-month FU with items from the previous DIA-LINK studies requesting the burden due to the pandemic (rated on an 11-point scale from 0 - 10). | Baseline, 24-month FU | |
Other | Psychological resilience | Psychological resilience is assessed as control variable at baseline with the 13-item Resilience Scale (RS-13). | Baseline | |
Other | Social support | Social support is assessed as control variable at baseline, 12-month FU, and 24-month FU with the 3-item Oslo Social Support Scale (OSSS-3). | Baseline, 24-month FU | |
Other | Night eating | Night eating behaviors are assessed as control variable at baseline, 12-month FU, and 24-month FU with the Night Eating Questionnaire (NEQ). | Baseline, 24-month FU | |
Other | Stressful life events | Stressful life events during the past 12 months are assessed as control variable at baseline, 12-month FU, and 24-month FU using the Life Events Questionnaire (LEQ) (=the German "Fragebogen zu kritischen Lebensereignissen"; reflecting the overall burden due to stressful life events in the past year). | Baseline, 24-month FU | |
Primary | Prevalence of affective disorders at baseline (per diagnostic interview) | Diagnoses of affective disorders are assessed at baseline using the corresponding section of the Brief Diagnostic Interview for Mental Disorders (Mini-DIPS Open Access). | Baseline | |
Primary | Prevalence of anxiety disorders at baseline (per diagnostic interview) | Diagnoses of anxiety disorders are assessed at baseline using the corresponding section of the Brief Diagnostic Interview for Mental Disorders (Mini-DIPS Open Access). | Baseline | |
Primary | Prevalence of eating disorders at baseline (per diagnostic interview) | Diagnoses of eating disorders are assessed at baseline using the corresponding section of the Brief Diagnostic Interview for Mental Disorders (Mini-DIPS Open Access). | Baseline | |
Primary | Depressive symptoms: incidence at 24-month FU | Depressive symptoms are assessed with the Patient Health Questionnaire-9 (PHQ-9) at baseline, 6-month FU, 12-month FU, 18-month FU, and 24-month FU. Primary outcome is the incidence of depressive symptoms at 24-month FU compared to baseline. | Baseline, 24-month FU | |
Primary | Depressive symptoms: recovery at 24-month FU | Depressive symptoms are assessed with the Patient Health Questionnaire-9 (PHQ-9) at baseline, 6-month FU, 12-month FU, 18-month FU, and 24-month FU. Primary outcome is the recovery from depressive symptoms at 24-month FU compared to baseline. | Baseline, 24-month FU | |
Primary | Anxiety symptoms: incidence at 24-month FU | Anxiety symptoms are assessed with the Generalized Anxiety Disorders-7 (GAD-7) Questionnaire at baseline, 6-month FU, 12-month FU, 18-month FU, and 24-month. Primary outcome is the incidence of anxiety symptoms at 24-month FU compared to baseline. | Baseline, 24-month FU | |
Primary | Anxiety symptoms: recovery | Anxiety symptoms are assessed with the Generalized Anxiety Disorders-7 (GAD-7) Questionnaire at baseline, 6-month FU, 12-month FU, 18-month FU, and 24-month FU. Primary outcome is the recovery from anxiety symptoms at 24-month FU compared to baseline. | Baseline, 24-month FU | |
Primary | Diabetes distress over time | Diabetes distress is assessed with the Problem Areas in Diabetes Scale (PAID) at baseline, 6-month FU, 12-month FU, 18-month FU, and 24-month FU to detect changes in diabetes distress from baseline to 24-month FU. | Baseline, 24-month FU | |
Primary | Daily diabetes burdens over time | Daily diabetes burdens (daily diabetes distress) are assessed at baseline, 6-month FU, 12-month FU, 18-month FU, and 24-month FU over each 14 consecutive days using smartphone-based ecological momentary assessment with selected items of the Problem Areas in Diabetes Scale (PAID) adapted for daily assessment (rated on an 11-point scale from 0 - 10) to detect changes in daily burdens from baseline to 24-month FU. | Baseline, 24-month FU | |
Primary | Eating problems: incidence | Eating problems (=disordered eating behavior/eating disorder symptoms) are assessed with the Diabetes Eating Problems Survey-Revised (DEPS-R; a validated, self-report measure for eating problems of people with diabetes where generic eating disorder questionnaires yield significant false-positive rates due to specific eating behaviors and dietary requirements for diabetes) at baseline, 6-month FU, 12-month FU, 18-month FU, and 24-month FU. Primary outcome is the incidence of eating problems at 24-month FU compared to baseline. | Baseline, 24-month FU | |
Primary | Glycated hemoglobin (HbA1c) over time | HbA1c (glycated hemoglobin), a laboratory measure of average blood glucose over the past 8 to 12 weeks, is estimated/collected at baseline, 6-month FU, 12-month FU, 18-month FU, and 24-month FU from the participants to detect changes for glycated hemoglobin from baseline to 24-month FU. | Baseline, 24-month FU | |
Primary | Glycemic levels (CGM glucose) over time | In addition to the global parameter HbA1c, automatically recorded daily glucose values are obtained from participants where continuous glucose monitoring (CGM) devices are used. Available glucose data are extracted at baseline, 6-month FU, 12-month FU, 18-month FU, and 24-month FU for each over 14 consecutive days of CGM measurement - parallel to the daily EMA - to detect changes in glucose levels from baseline to 24-month FU. | Baseline, 24-month FU | |
Primary | Daily stress levels over time | Daily stress levels are assessed at baseline, 6-month FU, 12-month FU, 18-month FU, and 24-month FU over each 14 consecutive days using smartphone-based ecological momentary assessment with items from the previous DIA-LINK study (requesting the current stress level and specific stressors, rated on an 11-point scale from 0 - 10) to detect changes in daily stress levels from baseline to 24-month FU. | Baseline, 24-month FU | |
Secondary | General health state over time | The self-evaluated general self-rated health state is assessed at baseline, 12-month FU, and 24-month FU using the 8-item Short Form Health Survey (SF-8) to detect changes in the health state from baseline to 24-month FU. | Baseline, 24-month FU | |
Secondary | Subjective health over time | The subjective health state is assessed at baseline, 12-month FU, and 24-month FU using the visual analogue scale (VAS) of the EuroQol Five Dimensions Questionnaire (EQ-5D) to detect changes in subjective health from baseline to 24-month FU. | Baseline, 24-month FU | |
Secondary | Wellbeing over time | Wellbeing is assessed at baseline, 12-month FU, and 24-month FU using the WHO-Five Well-being Index (WHO-5) to detect changes in wellbeing from baseline to 24-month FU. | Baseline, 24-month FU | |
Secondary | General sleep quality over time | General sleep quality assessed at baseline, 6-month FU, 12-month FU, 18-month FU, and 24-month FU using items of the Pittsburgh Sleep Quality Index (PSQI) to detect changes in sleep quality from baseline to 24-month FU. | Baseline, 24-month FU | |
Secondary | Daily sleep quality over time | Daily sleep quality assessed at baseline, 6-month FU, 12-month FU, 18-month FU, and 24-month FU over each 14 days using smartphone-based ecological momentary assessment with selected PSQI items adapted for daily assessment (rated on an 11-point scale from 0 - 10) to detect changes in daily sleep quality from baseline to 24-month FU. | Baseline, 24-month FU | |
Secondary | Fear of diabetes complications over time | Fear of diabetes complications is assessed at baseline, 12-month FU, and 24-month FU with the short form of the Fear of Diabetes Complications Questionnaire (FDCQ; requesting frequencies of worries and fears regarding long-term complications of diabetes) to detect changes in fear levels from baseline to 24-month FU. | Baseline, 24-month FU | |
Secondary | Fear of hypoglycemia over time | Fear of hypoglycemia is assessed at baseline, 12-month FU, and 24-month FU with the short form of the Hypoglycemia Fear Survey II (HFS-II-SF; requesting hypoglycemia-related worries and avoidance behaviors) to detect changes in fear levels from baseline to 24-month FU. | Baseline, 24-month FU | |
Secondary | Diabetes acceptance over time | Diabetes acceptance is assessed at baseline, 12-month FU, and 24-month FU with a short form of the Diabetes Acceptance Scale (DAS) to detect changes in diabetes acceptance from baseline to 24-month FU. | Baseline, 24-month FU | |
Secondary | Daily eating problems over time | Eating problems in daily life are assessed at baseline, 6-month FU, 12-month FU, 18-month FU, and 24-month FU over each 14 consecutive days using smartphone-based ecological momentary assessment with items requesting specific problematic eating behaviors (rated on an 11-point scale from 0 - 10) to detect changes in daily eating problems from baseline to 24-month FU. | Baseline, 24-month FU | |
Secondary | Diabetes self-management over time | Diabetes self-management behaviors are assessed at baseline, 12-month FU, and 24-month FU with the revised Diabetes Self-Management Questionnaire-Revised (DSMQ-R) to detect changes in diabetes self-management from baseline to 24-month FU. | Baseline, 24-month FU | |
Secondary | Alcohol misuse over time | Alcohol abuse/misuse is assessed at baseline, 12-month FU, and 24-month FU using the 5-item alcohol module of the Patient Health Questionnaire (PHQ-D) to detect changes in alcohol use from baseline to 24-month FU. | Baseline, 24-month FU |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |